/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Trevi Therapeutics Inc Share Price Today: Live Updates & Key Insights

Trevi Therapeutics Inc share price today is $11.2, up -6.2%. The stock opened at $11.61 against the previous close of $11.94, with an intraday high of $11.61 and low of $10.82.

Trevi Therapeutics Inc Share Price Chart

style
pb-0

Trevi Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Trevi Therapeutics Inc Share Price Performance

$11.2 -0.062(-6.2%) TRVI at 13 Mar 2026 03:35 PM Biotechnology
Lowest Today 10.82
Highest Today 11.61
Today’s Open 11.61
Prev. Close 11.94
52 Week High 14.39
52 Week Low 4.85
Day’s Range: Low 10.82 High 11.61
52-Week Range: Low 4.85 High 14.39
1 day return -
1 Week return -15.57
1 month return +7.88
3 month return -10.95
6 month return +39.03
1 year return +78.37
3 year return +492.08
5 year return +303.59
10 year return -

Trevi Therapeutics Inc Institutional Holdings

NEA Management Company, LLC 10.31

Frazier Life Sciences Management, L.P. 8.00

BlackRock Inc 7.72

FMR Inc 5.07

Vanguard Group Inc 5.02

Vivo Capital, LLC 3.97

Marshall Wace Asset Management Ltd 3.78

Morgan Stanley - Brokerage Accounts 3.35

AllianceBernstein L.P. 3.35

Rubric Capital Management LP 2.94

Vanguard Total Stock Mkt Idx Inv 2.67

MPM Oncology Impact Management LP 2.66

Wellington Management Company LLP 2.65

Orbimed Advisors, LLC 2.58

Viking Global Investors LP 2.49

Octagon Capital Advisors LP 2.20

Eventide Asset Management, LLC 2.05

Eventide Healthcare & Life Sciences I 2.05

Fidelity Select Biotechnology 1.98

Siren, L.L.C. 1.78

Geode Capital Management, LLC 1.73

State Street Corp 1.73

iShares Russell 2000 ETF 1.73

Logos Global Management LP 1.72

MEDICAL BioHealth EUR Acc 1.09

AB Small Cap Growth A 1.03

Fidelity Small Cap Growth 1.01

Vanguard Institutional Extnd Mkt Idx Tr 0.88

Biotech Growth Ord 0.80

Fidelity Select Health Care 0.78

Fidelity Small Cap Index 0.70

Principal SmallCap Growth I Instl 0.63

iShares Russell 2000 Growth ETF 0.59

Fidelity Small Cap Growth K6 0.50

iShares Biotechnology ETF 0.49

BlackRock Advantage Small Cap Core Instl 0.45

Emerald Growth A 0.45

Wellington Global Hlthcr Eq USD G Ac 0.43

Fidelity Extended Market Index 0.43

State St Russell Sm/Mid Cp® Indx SL Cl I 0.42

Trevi Therapeutics Inc Market Status

Strong Buy: 7

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Trevi Therapeutics Inc Fundamentals

Market Cap 1531.07 M

PB Ratio 7.9456

PE Ratio 0.0

Enterprise Value 1313.88 M

Total Assets 110.90 M

Volume 1011700

Trevi Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-26749000 -26.7M, FY22:-29152000 -29.2M, FY21:-33940000 -33.9M, FY20:-32758000 -32.8M, FY19:-26050000 -26.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-38000 -0.0M, Q1/2025:-37000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-38000 -0.0M

Quarterly Net worth Q3/2025:-11802000 -11.8M, Q2/2025:-12301000 -12.3M, Q1/2025:-10340000 -10.3M, Q3/2024:-13242000 -13.2M, Q2/2024:-12352000 -12.4M

About Trevi Therapeutics Inc & investment objective

Company Information Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Organisation Biotechnology

Employees 34

Industry Biotechnology

CEO Ms. Jennifer L. Good

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow